Trial Profile
Treatment of Neuroendocrine Tumors (NETs) With Combination of Everolimus and Radiolabeled Somatostatin Analogue
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 05 Aug 2020
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Lutetium-(177Lu)-oxodotreotide (Primary)
- Indications Neuroendocrine tumours
- Focus Adverse reactions
- 19 Jan 2019 Results (n=11) presented at the 2019 Gastrointestinal Cancers Symposium
- 21 Aug 2018 New trial record